Thrombolytics for hyperacute stroke in children

Pediatric Hematology and Oncology

Volumn 26, Issue 3, 2009, Pages 103-107

  Amlie Lefond, Catherine ^a   Fullerton, Heather J ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Stroke; Thrombolytics

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT;

ANAPHYLAXIS; BRAIN HEMORRHAGE; CHILD; CHILD CARE; CLINICAL PROTOCOL; DRUG INDICATION; EMBOLECTOMY; FIBRINOLYTIC THERAPY; HUMAN; LARYNX EDEMA; NOTE; RISK BENEFIT ANALYSIS; STROKE; ACUTE DISEASE; METHODOLOGY; REVIEW;

ACUTE DISEASE; CHILD; FIBRINOLYTIC AGENTS; HUMANS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 67651163590     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010902773230     Document Type: Note

References (31)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
2. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med. 1999;340:1781-1787.
3. deVeber GA, MacGregor D, Curtis R, Mayank S. Neurologic outcome in survivors of childhood arterial ischemic stroke and sinovenous thrombosis. J Child Neurol. 2000;15:316-324.
4. Fullerton HJ, Chetkovich DM, Wu YW, Smith WS, Johnston SC. Deaths from stroke in US children, 1979 to 1998. Neurology. 2002;59:34-39.
5. Ganesan V, Hogan A, Shack N, Gordon A, Isaacs E, Kirkham FJ. Outcome after ischaemic stroke in childhood. Dev Med Child Neurol. 2000;42:455-461.
6. Lo W, Zamel K, Ponnappa K, et al. The cost of pediatric stroke care and rehabilitation. Stroke. 2008;39:161-165.
7. Cannon BC, Kertesz NJ, Friedman RA, Fenrich AL. Use of tissue plasminogen activator in a stroke after radiofrequency ablation of a left-sided accessory pathway. J Cardiovasc Electrophysiol. 2001;12:723-725.
8. Carlson MD, Leber S, Deveikis J, Silverstein FS. Successful use of rt-PA in pediatric stroke. Neurology. 2001;57:157-158.
9. Losurdo G, Giacchino R, Castagnola E, et al. Cerebrovascular disease and varicella in children. Brain Dev. 2006;28:366-370.
10. Noser EA, Felberg RA, Alexandrov AV. Thrombolytic therapy in an adolescent ischemic stroke. J Child Neurol. 2001;16:286-288.
11. Shuayto MI, Lopez JI, Greiner F. Administration of intravenous tissue plasminogen activator in a pediatric patient with acute ischemic stroke. J Child Neurol. 2006;21:604-606.
12. Thirumalai SS, Shubin RA. Successful treatment for stroke in a child using recombinant tissue plasminogen activator. J Child Neurol. 2000;15:558.
13. Scott PA, Silbergleit R. Misdiagnosis of stroke in tissue plasminogen activator-treated patients: Characteristics and outcomes. Ann Emerg Med. 2003;42:611-618.
14. Shellhaas RA, Smith SE, O'Tool E, Licht DJ, Ichord RN. Mimics of childhood stroke: Characteristics of a prospective cohort 27018. Pediatrics. 2006;118:704-709.
15. Kahn JH, Viereck J, Kase C, et al. The use of intravenous recombinant tissue plasminogen activator in acute ischemic stroke. J Emerg Med. 2005;29:273-277.
16. McGlennan C, Ganesan V. Delays in investigation and management of acute arterial ischaemic stroke in children. Dev Med Child Neurol. 2008;50:537-540.
17. Del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke. 1998;29:4-11.
18. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA .1999;282:2003-2011.
19. Qureshi AI, Suri MF, Shatla AA, et al. Intraarterial recombinant tissue plasminogen activator for ischemic stroke: An accelerating dosing regimen. Neurosurgery. 2000;47:473-476.
20. Zaidat OO, Suarez JI, Santillan C, et al. Response to intra-arterial and combined intravenous and intra-arterial thrombolytic therapy in patients with distal internal carotid artery occlusion. Stroke. 2002;33:1821-1826.
21. Lutsep HL, Rymer MM, Nesbit GM. Vertebrobasilar revascularization rates and outcomes in the MERCI and multi-MERCI trials. J Stroke Cerebrovasc Dis. 2008;17:55-57.
22. Molina CA, Saver JL. Extending reperfusion therapy for acute ischemic stroke: Emerging pharmacological, mechanical, and imaging strategies. Stroke. 2005;36:2311-2320.
23. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood. 1992;80:1998-2005.
24. Monagle P,Barnes C, Ignjatovic V, et al. Developmental haemostasis: Impact for clinical haemostasis laboratories. Thromb Haemost. 2006;95:362-372.
25. Parmar N, Albisetti M, Berry LR, Chan AK. The fibrinolytic system in newborns and children. Clin Lab. 2006;52:115-124.
26. Siegbahn A, Ruusuvaara L. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Thromb Haemost. 1988;60:361-364.
27. Wang M, Hays T, Balasa V, et al. Low-dose tissue plasminogen activator thrombolysis in children. J Pediatr Hematol Oncol. 2003;25:379-386.
28. Amlie-Lefond C, Chan A, Ichord R, deVeber G, and members of the IPSS. tPA in children with arterial ischemic stroke: Cases from the IPSS compared with the literature-based cases. J Thromb Haemost. 2007;5(suppl 2): 579.
29. Ganesan V, Chong WK, Cox TC, Chawda SJ, Prengler M, Kirkham FJ. Posterior circulation stroke in childhood: Risk factors and recurrence. Neurology. 2002;59:1552-1556.
30. Kirton A, Wong JH, Mah J, et al. Successful endovascular therapy for acute basilar thrombosis in an adolescent. Pediatrics. 2003;112(3 Pt 1):e248-e251.
31. Roach ES, Golomb MR, Adams R, et al. Management of stroke in infants and children: A Scientific Statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke. 2008;39:2644-2691.